Method for delivering bioactive agents into and through the mucosally associated lymphoid tissues and controlling their release
BRIEF DESCRIPTION OF THE FIGURES DETAILED DESCRIPTION OF THE INVENTION I. MICROENCAPSULATION A. Preparation of Dye-Loaded Microcapsules. B. Preparation of Antigen-Loaded Microcapsules. II. PENETRATION... Read More
Inventors: Tice, Thomas R.; Gilley, Richard M.; Eldridge, John H.; Staas, Jay K.;, Assignee: Southern Research Institute (Birmingham, AL); The UAB Research Foundation (Birmingham, AL) |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
This invention relates to active core materials such as biologically active agent(s), drug(s), or substance(s) encapsulated within a biodegradable-biocompatable polymeric matrix. In view of the enormo... Read More
Inventors: Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Jarboe, Daniel L.; Cassels, Frederick; Brown, William; Thies, Curt; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil;, Assignee: The United States of America as represented by the Secretary of the Army (Washington, DC) |
Specific binding agents for KSHV vIL-6 that neutralize a biological activity
1. A monoclonal antibody that specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), wherein the monoclonal antibody is produced by a hybridoma deposited as American ... Read More
Inventors: Aoki, Yoshiyasu; Tosato, Giovanna;, Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC) |
Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
The present invention relates to a method of preparing a soluble, hetero-oligomeric mammalian polypeptide by culturing a host cell transformed or transfected with an expression vector encoding a fusio... Read More
Inventors: Ciardelli, Thomas L.; Johnson, Kirk;, Assignee: Chiron Corporation (Emeryville, CA); Trustee of Dartmouth College (Hanover, NH) |
Hepatitis C virus inhibitors
OF THE INVENTION As used herein, the following definitions apply unless otherwise noted. With reference to the instances where (R) or (S) is used to designate the configuration of a substituent in co... Read More
Inventors: Campbell, Jeffrey Allen; Good, Andrew;, Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |
Polynucleotide encoding TNFL1
It is an object of the invention to provide new members of the TNF and TNFR families, as well as methods of screening for compounds capable of modifying the activities of these proteins. This and othe... Read More
Inventors: Tribouley, Catherine;, Assignee: Chiron Corporation (Emeryville, CA) |
Inhibiting apoptosis with adenovirus RID protein
In accordance with the present invention, the inventor herein has succeeded in discovering that the Ad 10.4K/14.5K complex inhibits apoptosis mediated by death receptors, in particular Fas or TNFR-1, ... Read More
Inventors: Wold, William S. M.;, Assignee: Saint Louis University (St. Louis, MO) |
Solid fat nanoemulsions as vaccine delivery vehicles
The present invention provides pharmaceutical compositions comprising nanoemulsions of particles comprising a lipid core composed of a lipid which is in a solid or liquid crystalline phase at at least... Read More
Inventors: Anselem, Shimon; Lowell, George H.; Aviv, Haim; Friedman, Doron;, Assignee: Pharmos Corporation (New York, NY); The United States of America as represented by the Secretary of the Army (Washington, DC) |
Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
The present invention overcomes the problems and disadvantages of the prior art by providing a method for isolating and purifying the lactoferrin and transferrin receptor proteins thereby facilitating... Read More
Inventors: Schryvers, Anthony B.;, Assignee: The Board of Governors of the University (Alberta, CA) |
Outer membrane protein B1 of Moraxella catarrhalis
OF THE INVENTION Definitions By the terms "OMP B1", and "B1 protein" are meant, for the purposes of the specification and claims, to refer to a protein having the following distinguishing and functio... Read More
Inventors: Campagnari, Anthony A.;, Assignee: The Research Foundation of the State University of New York (Amherst, NY) |
Transferrin receptor protein of moraxella
What we claim is: 1. A method of producing an isolated and purified non-denatured transferrin receptor protein of a Moraxella catarrhalis strain having an apparent molecular mass of about 80 to about ... Read More
Inventors: Yang, Yan-Ping; Myers, Lisa E.; Harkness, Robin E.; Klein, Michel H.;, Assignee: Connaught Laboratories Limited (Toronto, CA) |
Vaccine against mumps containing a jeryl-lynn virus strain
1. A combined vaccine comprising a substantially homogeneous immunogenic Jeryl-Lynn isolate, an attenuated measles virus, an attenuated rubella virus, and an agent for protection against varicella zos... Read More
Inventors: Harford, Nigel Maurice; Colau, Brigitte Desiree Alberte; Didelez, Jean;, Assignee: SmithKline Beecham Biologicals, s.a. (Rixensart, BE) |
DNA sequences which encode immunoreactive HCMV-specific peptides
We claim: 1. An isolated and purified DNA fragment consisting of HCMV DNA sequence, wherein said HCMV DNA sequence is contained within the DNA encoding amino acids 718-880 of the HCMV protein pp150, a... Read More
Inventors: Stuber, Werner; Wieczorek, Leszek; Ziegelmaier, Robert;, Assignee: Behringwerke Aktiengesellschaft (Marburg, DE) |
Vaccines absorbable by the transmucosal way
OF THE INVENTION The Applicants observed that when antigens, also of proteic nature, are coated with polysaccharides, they are absorbed by the mucosa and stimulate both local and humoral immunity. Fu... Read More
Inventors: Wyss, Rolando; Bizzini, Bernad; Volpato, Ivo;, Assignee: Grisotech S.A. (Soazza, CH) |
Method of detecting mycoplasma infection in poultry and compositions therefor
OF THE INVENTION As used herein, the term "antigen" refers to a protein, polypeptide, or Coomassie blue staining band purified by the method described below and proteins or polypeptides which are sub... Read More
Inventors: Avakian, Alan P.; Kleven, Stanley H.;, Assignee: The University of Georgia Research Foundation, Inc. (Athens, GA) |
FcεPE chimeric protein for targeted treatment of allergy responses, a method for its production and pharmaceutical compositions containing the same
OF THE INVENTION The Fc-PE chimeric protein according to the present invention has a number of advantages over the existing known drugs.: 1. Specificity: Fc-PE is highly specific, affecting the cel... Read More
Inventors: Fishman, Ala; Yarkoni, Shai; Lorberboumgalski, Haya;, Assignee: Yissum Research Company of the Hebrew University of Jerusalem (IL) |
Targeting of dosages of medicine and therapeutic agents
The embodiments of the invention from which an exclusive property of privilege is claimed are as follows: 1. A method of treating a disease or condition in a human treatable by a medicinal or therapeu... Read More
Inventors: Gustafson, Stefan;, Assignee: Hyal Pharmaceutical Corporation (Mississauga, CA) |
Method of delivering a protein to poultry
In accordance with the present invention, it has been discovered that a protein can be administered to domestic birds by whole-body spraying of the birds with an effective amount of a live avirulent d... Read More
Inventors: Kelly-Aehle, Sandra;, Assignee: Megan Health, Inc. (St. Louis, MO) |
Attenuated recombinant rabies virus mutants and live vaccines thereof
OF THE INVENTION Preferred mutants according to the invention may be obtained by deleting residues 143 to 149 or 139 to 149 of the phosphoprotein (P) of rabies virus and simultaneously replacing the ... Read More
Inventors: Mebatsion, Teshome;, Assignee: Akzo Nobel N.V. (Arnhem, NL) |
Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes
OF THE INVENTION The benefit of this invention is that the modified forms of HCV NS3 protease retain full activity, yet are highly amenable to biochemical experimentation because of their highly solu... Read More
Inventors: Wittekind, Michael; Weinheimer, Steven; Zhang, Yaqun; Goldfarb, Valentina;, Assignee: Bristol-Myers Squibb Company (Princeton, NJ) |
Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
In its broadest aspect, the present invention is directed to a monoclonal antibody, or binding fragment thereof, which specifically binds to antigens sharing a common epitope present on the surface of... Read More
Inventors: Gelber, Cohava;, Assignee: Molecular Discoveries, L.L.C. (New York, NY) |
Recombinant infectious laryngotracheitis virus and uses thereof
OF THE INVENTION The present invention provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short... Read More
Inventors: Wild, Martha A.; Cochran, Mark D.;, Assignee: Schering-Plough Animal Health (Summit, NJ) |
Growth differentiation factor-8
The present invention provides a cell growth and differentiation factor, GDF-8, a polynucleotide sequence which encodes the factor, and antibodies which are immunoreactive with the factor. This factor... Read More
Inventors: Lee, Se-Jin; McPherron, Alexandra C.;, Assignee: The Johns Hopkins University School of Medicine (Baltimore, MD) |
Staphylococcus antigen and vaccine
It is therefore an object of the present invention to provide an antigen common to a majority of clinically-significant strains from multiple species of Staphylococcus. It is a further object to prov... Read More
Inventors: Pavliak, Viliam; Fattom, Ali Ibrahim;, Assignee: NABI Biopharmaceuticals (Boca Raton, FL) |
Antigenic compositions and methods for using same
We claim: 1. An antigenic conjugate which is immunoreactive with anti-GM2 antibodies produced by mamallian tumors said antigenic conjugate consisting essentially of the oligosaccharide portion of GM2 ... Read More
Inventors: Irie, Reiko F.; Tai, Tadashi; Morton, Donald L.; Cahan, Leslie D.; Paulson, James C.;, Assignee: Regents of the University of California (Berkeley, CA) |
Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
In accordance with the invention, a multiple antigenic peptide system is disclosed that comprises a dendritic core and at least one peptide and a lipophilic membrane anchoring moiety attached thereto,... Read More
Inventors: Tam, James P.;, Assignee: |
Stress proteins and uses therefor
The present invention relates to stress proteins and methods of modulating an individual's (such as a human, other mammal or other vertebrate) immune response. In particular, it relates to the use of ... Read More
Inventors: Young, Richard A.;, Assignee: Whitehead Institute for Biomedical Research (Cambridge, MA) |
Methods for using heat shock proteins
OF THE PREFERRED EMBODIMENT Definitions For the purposes of the present invention, the term "toxin" refers to any chemical or substance which kills cells, renders them inactive or causes them to be u... Read More
Inventors: Wallen, Erik; Moseley, Pope L.;, Assignee: University of New Mexico (Albuquerque, NM) |
Induction of a Th1-like response in vitro
The invention is based on the discovery that a cell sample containing naive lymphocytes can be stimulated in vitro to exhibit a Th1-like response. Accordingly, the invention features a method of deter... Read More
Inventors: Siegel, Marvin; Chu, N. Randall; Mizzen, Lee A.;, Assignee: Stressgen Biotechnologies Corporation (Victoria, CA) |
Method for producing cell-fushion type morbillivirus mutants
What is claimed is: 1. A method for reducing the cell-fusion ability of a virus comprising introducing a mutation in vitro to a position corresponding to the 278.sup.th amino acid in a protein of the ... Read More
Inventors: Komase, Katsuhiro; Nakayama, Tetsuo; Aizawa, Chikara;, Assignee: The Kitasata Institute (Tokyo, JP) |
Drugs 
